268 related articles for article (PubMed ID: 30869793)
1. Potential Role of Metal Chelation to Prevent the Cardiovascular Complications of Diabetes.
Calderon Moreno R; Navas-Acien A; Escolar E; Nathan DM; Newman J; Schmedtje JF; Diaz D; Lamas GA; Fonseca V
J Clin Endocrinol Metab; 2019 Jul; 104(7):2931-2941. PubMed ID: 30869793
[TBL] [Abstract][Full Text] [Related]
2. Chelation therapy to prevent diabetes-associated cardiovascular events.
Diaz D; Fonseca V; Aude YW; Lamas GA
Curr Opin Endocrinol Diabetes Obes; 2018 Aug; 25(4):258-266. PubMed ID: 29846236
[TBL] [Abstract][Full Text] [Related]
3. EDTA Chelation Therapy to Reduce Cardiovascular Events in Persons with Diabetes.
Ouyang P; Gottlieb SH; Culotta VL; Navas-Acien A
Curr Cardiol Rep; 2015 Nov; 17(11):96. PubMed ID: 26364188
[TBL] [Abstract][Full Text] [Related]
4. Possible differential benefits of edetate disodium in post-myocardial infarction patients with diabetes treated with different hypoglycemic strategies in the Trial to Assess Chelation Therapy (TACT).
Escolar E; Ujueta F; Kim H; Mark DB; Boineau R; Nahin RL; Goertz C; Lee KL; Anstrom KJ; Lamas GA
J Diabetes Complications; 2020 Aug; 34(8):107616. PubMed ID: 32446881
[TBL] [Abstract][Full Text] [Related]
5. The effect of an EDTA-based chelation regimen on patients with diabetes mellitus and prior myocardial infarction in the Trial to Assess Chelation Therapy (TACT).
Escolar E; Lamas GA; Mark DB; Boineau R; Goertz C; Rosenberg Y; Nahin RL; Ouyang P; Rozema T; Magaziner A; Nahas R; Lewis EF; Lindblad L; Lee KL
Circ Cardiovasc Qual Outcomes; 2014 Jan; 7(1):15-24. PubMed ID: 24254885
[TBL] [Abstract][Full Text] [Related]
6. Heavy Metals, Cardiovascular Disease, and the Unexpected Benefits of Chelation Therapy.
Lamas GA; Navas-Acien A; Mark DB; Lee KL
J Am Coll Cardiol; 2016 May; 67(20):2411-2418. PubMed ID: 27199065
[TBL] [Abstract][Full Text] [Related]
7. The effect of EDTA-based chelation on patients with diabetes and peripheral artery disease in the Trial to Assess Chelation Therapy (TACT).
Ujueta F; Arenas IA; Escolar E; Diaz D; Boineau R; Mark DB; Golden P; Lindblad L; Kim H; Lee KL; Lamas GA
J Diabetes Complications; 2019 Jul; 33(7):490-494. PubMed ID: 31101487
[TBL] [Abstract][Full Text] [Related]
8. Edetate Disodium-Based Treatment for Secondary Prevention in Post-Myocardial Infarction Patients.
Lamas GA; Issa OM
Curr Cardiol Rep; 2016 Feb; 18(2):20. PubMed ID: 26797807
[TBL] [Abstract][Full Text] [Related]
9. Enhanced vasculotoxic metal excretion in post-myocardial infarction patients following a single edetate disodium-based infusion.
Arenas IA; Navas-Acien A; Ergui I; Lamas GA
Environ Res; 2017 Oct; 158():443-449. PubMed ID: 28689036
[TBL] [Abstract][Full Text] [Related]
10. Chronic Toxic Metal Exposure and Cardiovascular Disease: Mechanisms of Risk and Emerging Role of Chelation Therapy.
Aneni EC; Escolar E; Lamas GA
Curr Atheroscler Rep; 2016 Dec; 18(12):81. PubMed ID: 27822681
[TBL] [Abstract][Full Text] [Related]
11. The trial to assess chelation therapy 2 (TACT2): Rationale and design.
Lamas GA; Anstrom KJ; Navas-Acien A; Boineau R; Kim H; Rosenberg Y; Stylianou M; Jones TLZ; Joubert BR; Santella RM; Escolar E; Aude YW; Fonseca V; Elliott T; Lewis EF; Farkouh ME; Nathan DM; Mon AC; Gosnell L; Newman JD; Mark DB;
Am Heart J; 2022 Oct; 252():1-11. PubMed ID: 35598636
[TBL] [Abstract][Full Text] [Related]
12. Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: the TACT randomized trial.
Lamas GA; Goertz C; Boineau R; Mark DB; Rozema T; Nahin RL; Lindblad L; Lewis EF; Drisko J; Lee KL;
JAMA; 2013 Mar; 309(12):1241-50. PubMed ID: 23532240
[TBL] [Abstract][Full Text] [Related]
13. Baseline characteristics including blood and urine metal levels in the Trial to Assess Chelation Therapy 2 (TACT2).
Navas-Acien A; Santella RM; Joubert BR; Huang Z; Lokhnygina Y; Ujueta F; Gurvich I; LoIacono NJ; Ravalli F; Ward CD; Jarrett JM; Salazar AL; Boineau R; Jones TLZ; Mark DB; Newman JD; Nathan DM; Anstrom KJ; Lamas GA
Am Heart J; 2024 Jul; 273():72-82. PubMed ID: 38621575
[TBL] [Abstract][Full Text] [Related]
14. Chelation therapy in cardiovascular disease: an update.
Sultan S; Murarka S; Jahangir A; Mookadam F; Tajik AJ; Jahangir A
Expert Rev Clin Pharmacol; 2017 Aug; 10(8):843-854. PubMed ID: 28597699
[TBL] [Abstract][Full Text] [Related]
15. Chelation therapy to treat atherosclerosis, particularly in diabetes: is it time to reconsider?
Lamas GA; Ergui I
Expert Rev Cardiovasc Ther; 2016 Aug; 14(8):927-38. PubMed ID: 27149141
[TBL] [Abstract][Full Text] [Related]
16. Chelation Therapy as a Cardiovascular Therapeutic Strategy: the Rationale and the Data in Review.
Mathew RO; Schulman-Marcus J; Nichols EL; Newman JD; Bangalore S; Farkouh M; Sidhu MS
Cardiovasc Drugs Ther; 2017 Dec; 31(5-6):619-625. PubMed ID: 29129003
[TBL] [Abstract][Full Text] [Related]
17. Differential Outcomes With Edetate Disodium-Based Treatment Among Stable Post Anterior vs. Non-Anterior Myocardial Infarction Patients.
Lewis EF; Ujueta F; Lamas GA; Roberts RS; Mark DB; Nahin RL; Goertz C; Stylianou M; Lee KL
Cardiovasc Revasc Med; 2020 Nov; 21(11):1389-1395. PubMed ID: 32303436
[TBL] [Abstract][Full Text] [Related]
18. Chelation therapy and cardiovascular disease: connecting scientific silos to benefit cardiac patients.
Peguero JG; Arenas I; Lamas GA
Trends Cardiovasc Med; 2014 Aug; 24(6):232-40. PubMed ID: 25106084
[TBL] [Abstract][Full Text] [Related]
19. Chelation therapy after the trial to assess chelation therapy: results of a unique trial.
Avila MD; Escolar E; Lamas GA
Curr Opin Cardiol; 2014 Sep; 29(5):481-8. PubMed ID: 25023079
[TBL] [Abstract][Full Text] [Related]
20. Chelation therapy for the management of diabetic complications: a hypothesis and a proposal for clinical laboratory assessment of metal ion homeostasis in plasma.
Frizzell N; Baynes JW
Clin Chem Lab Med; 2014 Jan; 52(1):69-75. PubMed ID: 23612664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
